Role of the neuropathology of Alzheimer disease in dementia in the oldest-old

James J. Peters VA Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468, USA.
Archives of neurology (Impact Factor: 7.01). 10/2008; 65(9):1211-7. DOI: 10.1001/archneur.65.9.1211
Source: PubMed

ABSTRACT Neuritic plaques (NPs) and neurofibrillary tangles (NFTs) in the brain, especially in the hippocampus, entorhinal cortex, and isocortex, are hallmark lesions of Alzheimer disease and dementia in the elderly. However, this association has not been extensively studied in the rapidly growing population of the very old.
To assess the relationship between estimates of cognitive function and NP and NFT pathologic conditions in 317 autopsied persons aged 60 to 107 years.
We studied the relationship between severity of dementia and the density of these characteristic lesions of Alzheimer disease in young-old, middle-old, and oldest-old persons. The relationship of the severity of dementia as measured by the Clinical Dementia Rating scale to the density of NPs and NFTs was then assessed in each age group.
Three hundred seventeen brains of persons aged 60 years and older were selected to have either no remarkable neuropathological lesions or only NP and NFT lesions. Brains with any other neuropathological conditions, either alone or in addition to Alzheimer disease findings, were excluded. The study cohort was then stratified into the youngest quartile (aged 60-80 years), middle 2 quartiles (aged 81-89 years), and oldest quartile (aged 90-107 years).
While the density of NPs and NFTs rose significantly by more than 10-fold as a function of the severity of dementia in the youngest-old group, significant increases in the densities of NPs and NFTs were absent in the brains of the oldest-old. This lack of difference in the densities of NPs and NFTs was due to reduced lesion densities in the brains of oldest-old persons with dementia rather than to increased density of these lesions in the brains of nondemented oldest-old persons.
These findings suggest that the neuropathological features of dementia in the oldest-old are not the same as those of cognitively impaired younger-old persons and compel a vigorous search for neuropathological indices of dementia in this most rapidly growing segment of the elderly population.

Download full-text


Available from: Daniel P Perl, Aug 14, 2015
  • Source
    • "Alzheimer's disease (AD) is a progressive, neurodegenerative disease and the most common type of adultonset dementia (Cerpa et al., 2008). Although the etiologic and pathogenic events that lead to this disease are still unknown , highly typical neuropathological changes (amyloid plaques, neurofibrillary tangles and an intense glial reactivity ) are observed in the patients' brains (Maccioni et al., 2001; Watson et al., 2005; Haroutunian et al., 2008). Cholinergic dysfunction signaling is an early hallmark of AD (Ikonomovik et al., 2011), one of the most important being a reduction in Choline Acetyltransferase (ChAT) enzyme activity in the cholinergic neurons of the temporal and parietal cortices, the hippocampus, the entorhinal cortex, and the amygdala (Mufson et al., 2003; Abel et al., 2008; Geula et al., 2008) Decreased ChAT activity in the cerebral cortex has been reported to be related to the severity of Alzheimer's Disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Decreased Choline Acetyltransferase (ChAT) brain level is one of the main biochemical disorders in Alzheimer's Disease (AD). In rodents, recent data show that the CHAT gene can be regulated by a neural restrictive silencer factor (NRSF). The aim of the present work was to evaluate the gene and protein expression of CHAT and NRSF in frontal, temporal, entorhinal and parietal cortices of AD patient brains. Four brains from patients with AD and four brains from subjects without dementia were studied. Cerebral tissues were obtained and processed by the guanidine isothiocyanate method for RNA extraction. CHAT and NRSF gene and protein expression were determined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. CHAT gene expression levels were 39% lower in AD patients as compared to the control group (p < 0.05, U test). ChAT protein levels were reduced by 17% (p = 0.02, U test). NRSF gene expression levels were 86% higher in the AD group (p = 0.001, U test) as compared to the control group. In the AD subjects, the NRSF protein levels were 57% higher (p > 0.05, U test) than in the control subjects. These findings suggest for the first time that in the brain of AD patients high NRSF protein levels are related to low CHAT gene expression levels.
    Genetics and Molecular Biology 03/2013; 36(1):28-36. DOI:10.1590/S1415-47572013000100005 · 0.88 Impact Factor
  • Source
    • "There is a large overlap in the presence of neuropathological abnormalities between elderly with and those without dementia. In several large autopsy series, it has consistently been shown that the association of plaques and tangles with clinical dementia steadily weakens with increasing age [3] [5] [6]. Over the age of 80, plaques and tangles simply are poor markers of dementia (Fig. 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The focus of most of the research on Alzheimer's disease in the last decades has been on senile plaques and neurofibrillary tangles. The vast majority of patients with Alzheimer's disease are over 75 years of age, whereas most of the research focuses on younger subjects. To consider old-age dementia as a homogenous well-defined condition ignores the complexity of this condition and limits the development of new diagnostic methods, preventive strategies, or treatment strategies that could be widely applicable in daily practice in the majority of the older patients. The current research on biomarkers focuses on correlates of plaques and tangles, which are poor markers in older dementia subjects. Acknowledging that dementia in old age is an essentially different condition from dementia at relatively younger age is needed and should lead to new approaches in dementia research.
    Journal of Alzheimer's disease: JAD 07/2012; 31:S203-9. DOI:10.3233/JAD-2012-112216 · 4.15 Impact Factor
  • Source
    • "The Baltimore Longitudinal Study of Aging (BLSA) (O'Brien et al., 2009), the Honolulu-Asia Aging Study (White, 2009), and the Medical Research Council Cognitive Function and Ageing Study (Savva et al., 2009) have similarly reported dissociations between plaques, tangles, or other pathological lesions and cognition. This relatively poor correlation may become even more pronounced in the oldest old (Haroutunian et al., 2008; Ewbank and Arnold, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although neuritic plaques and neurofibrillary tangles in older adults are correlated with cognitive impairment and severity of dementia, it has long been recognized that the relationship is imperfect, as some people exhibit normal cognition despite high levels of Alzheimer's disease (AD) pathology. We compared the cellular, synaptic, and biochemical composition of midfrontal cortices in female subjects from the Religious Orders Study who were stratified into three subgroups: (1) pathological AD with normal cognition ("AD-Resilient"), (2) pathological AD with AD-typical dementia ("AD-Dementia"), and (3) pathologically normal with normal cognition ("Normal Comparison"). The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared with the AD-Dementia group, and increased densities of glial fibrillary acidic protein astrocytes compared with both the AD-Dementia and Normal Comparison groups. Further, in a discovery-type antibody microarray protein analysis, we identified a number of candidate protein abnormalities that were associated with a particular diagnostic group. These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.
    Neurobiology of aging 05/2012; 34(1). DOI:10.1016/j.neurobiolaging.2012.03.004 · 4.85 Impact Factor
Show more